HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio

Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been issued a notice of patent allowance from the Brazilian Patent and Trademark Office (Number BRI 12018005982-0) and the United Arab Emirates Ministry of Economy, Intellectual Property Protection Department (Number P6000433/18). These new patent awards increase HeartSciences' patent portfolio to now include 33 international granted or allowed patents and 9 US granted patents covering well over 100 claims.

"AI is now in daily use in healthcare and is expected to reinvent the ability of an ECG to screen for heart disease. We are pleased to further strengthen our extensive intellectual property portfolio as AI is expected to drive significant growth in the ECG market. HeartSciences is a leader in AI-based ECG technology being used in everyday clinical practice, and with the recent signing of agreements with Mount Sinai, a top-ranked hospital in cardiology, we expect to significantly expand our ECG cardiovascular disease screening capabilities," said Andrew Simpson, CEO of HeartSciences.